Designing Long-Term Follow-Up Studies for Gene and Cell Therapies Designing Long-Term Follow-Up Studies for Gene and Cell Therapies Long-term follow-up studies for gene and cell therapies are critical to evaluating safety and efficacy over an extended period. In the U.S. regulatory context, these studies often form part of post-market commitments after a product’s approval by regulatory bodies such as the FDA. This guide will detail the systematic framework for designing such studies, focusing on patient registries and associated practices critical to compliance and data integrity. Step 1: Understanding Regulatory Requirements for Long-Term Follow-Up Studies Before initiating a long-term follow-up study,…

ATMP GMP Inspection Readiness Evidence Pack in 2023 – Playbook 3 ATMP GMP Inspection Readiness Evidence Pack in 2023 – Playbook 3 Understanding ATMP GMP Regulations and Guidelines In the context of Advanced Therapy Medicinal Products (ATMPs), compliance with Good Manufacturing Practice (GMP) is paramount. The requirements set forth by regulations such as Annex 1 (regarding sterility), Annex 2 (regarding ATMPs), and current industry standards shape your activities from preclinical development to commercialization. To initiate the ATMP GMP journey, one must first understand these regulations fully. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)…

How to Defend Comparability After Manufacturing Site Changes in : Evidence Pack How to Defend Comparability After Manufacturing Site Changes in : Evidence Pack This article serves as a comprehensive guide for regulatory affairs professionals, CMC scientists, and clinical development teams focusing on the defense of comparability in Advanced Therapy Medicinal Products (ATMPs) after changes in manufacturing site. It aligns with FDA regulations and ICH guidelines, helping stakeholders navigate the complexities involved in comparability protocols, critical quality attributes (CQAs), potency assays, and reference standards essential for compliance. Step 1: Understanding the Concept of Comparability Comparability assessment is a fundamental principle…

ATMP GMP Inspection Readiness Evidence Pack in 2023 – Playbook 2 ATMP GMP Inspection Readiness Evidence Pack in 2023 – Playbook 2 The manufacturing and development of Advanced Therapy Medicinal Products (ATMPs) significantly hinges on compliance with Good Manufacturing Practice (GMP) regulations. In this playbook, we outline a comprehensive step-by-step guide for ensuring GMP inspection readiness specifically tailored for ATMP developers and manufacturers. This guide emphasizes practical actions and documentation expectations to help you navigate the complexities of regulatory compliance. Step 1: Understand the Regulatory Framework for ATMPs Before preparing for GMP inspections, it is crucial to have a clear…

Reference Standard Strategy for Complex ATMP Assays in 2023: Qualification and Lifecycle Reference Standard Strategy for Complex ATMP Assays in 2023: Qualification and Lifecycle In the landscape of Advanced Therapy Medicinal Products (ATMPs), the establishment of reference standards plays a crucial role in ensuring the accuracy, reliability, and comparability of complex assay results. This guide provides a comprehensive, step-by-step approach to developing a Reference Standard Strategy in alignment with the standards set forth by the European Medicines Agency (EMA) and Good Clinical Practice (GCP). This article aims at regulatory affairs professionals, clinical development teams, and quality assurance personnel who seek…

ATMP GMP Inspection Readiness Evidence Pack in 2023 – Playbook 1 ATMP GMP Inspection Readiness Evidence Pack in 2023 – Playbook 1 The development and commercialization of Advanced Therapy Medicinal Products (ATMPs) require adherence to stringent Good Manufacturing Practice (GMP) regulations. This comprehensive guide provides a structured approach to preparing for GMP inspections relevant to ATMP manufacturing, focusing on the evidence pack necessary for regulatory compliance in the United States. Step 1: Understand the Regulatory Framework for ATMPs Before initiating any activities related to ATMP manufacturing, it’s crucial to grasp the regulatory framework established by various health authorities. The U.S….

Potency Assay Validation Plan for Cell/Gene Therapies in 2024: Acceptance Criteria and Trending Potency Assay Validation Plan for Cell/Gene Therapies in 2024: Acceptance Criteria and Trending The evaluation of potency is crucial for the development and approval of Advanced Therapy Medicinal Products (ATMP), including cell and gene therapies. This article provides a comprehensive step-by-step tutorial on creating a robust potency assay validation plan, focusing on acceptance criteria and trending relevant for 2024. Understanding these regulations and guidelines will play an essential role in your regulatory affairs, comparative protocols, and ensure adherence to clinical quality attributes (CQAs). Our focus will be…

Analytical Characterization Strategy for Viral Vectors in 2023: Orthogonal Methods and CQAs Analytical Characterization Strategy for Viral Vectors in 2023: Orthogonal Methods and CQAs The development of Advanced Therapy Medicinal Products (ATMPs), specifically gene therapies that utilize viral vectors, requires a robust analytical characterization strategy to ensure product quality and patient safety. This guide outlines a step-by-step approach for regulatory professionals engaged in the gene therapy sector, detailing effective analytical methods, critical quality attributes, and the necessary documentation for compliance with FDA regulations. By following these guidelines, organizations can facilitate successful regulatory submissions and ensure the establishment of comparability protocols…

Technology Transfer Playbook for ATMPs in 2023: From Clinical to Commercial Scale Technology Transfer Playbook for ATMPs in 2023: From Clinical to Commercial Scale As the pharmaceutical landscape continues to evolve, the transfer of Advanced Therapy Medicinal Products (ATMPs) from clinical to commercial scale becomes an increasingly paramount concern. This technology transfer presents unique challenges that necessitate a systematic approach to ensure compliance with Good Manufacturing Practices (GMP), stringent regulatory requirements, and robust quality controls. This guide serves as a comprehensive playbook for AMTP regulatory consulting, outlining the essential steps to facilitate a seamless transition from the clinical phase to…

Comparability Protocol Consulting for ATMPs in 2023: When to Use and How to Get Buy-In Comparability Protocol Consulting for ATMPs in 2023: When to Use and How to Get Buy-In As the landscape of Advanced Therapy Medicinal Products (ATMPs) continues to evolve, regulatory compliance and the management of product changes become paramount. The use of comparability protocols is essential for ensuring that product quality, safety, and efficacy are maintained throughout the product lifecycle. This article provides a detailed step-by-step tutorial on how to effectively utilize comparability protocols in ATMP regulatory consulting. Step 1: Understanding Comparability Protocols The complexity of ATMPs…